NYSEMKT: ZOMZomedica Corp Stock
$0.13+0.00 (+0%)
Updated Apr 24, 2024
ZOM Price
$0.13
Fair Value Price
N/A
Market Cap
$127.39M
52 Week Low
$0.12
52 Week High
$0.25
P/E
-3.71x
P/B
0.53x
P/S
7.79x
PEG
N/A
Dividend Yield
N/A
Revenue
$25.19M
Earnings
-$33.64M
Gross Margin
68.8%
Operating Margin
-138.15%
Profit Margin
-133.6%
Debt to Equity
0.06
Operating Cash Flow
-$16M
Beta
0.9
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ZOM Overview
Zomedica Pharmaceuticals Corp. operates as a development stage veterinary diagnostic and pharmaceutical company. The company is headquartered in Ann Arbor, Michigan and currently employs 27 full-time employees. The firm is engaged in developing products for companion animals, such as canine, feline, and equine by focusing on needs of clinical veterinarians. The company is focused on developing three diagnostic platforms, a Bulk Acoustic Wave sensor-based veterinary point-of-care diagnostic platform for performing immunodiagnostic testing, a Raman spectroscopy-based point-of-care diagnostic platform for the detection of pathogens, and liquid biopsy assays for the detection of cancer, along with related consumables. The Company’s TRUFORMA product candidate is an investigational device being developed as a point-of-care biosensor platform. ZM-020 is its diagnostic platform being developed to screen for a range of pathogens in companion animal feces, urine, respiratory, and dermatological samples. The company is developing ZM-017 as a canine cancer liquid biopsy platform.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ZOM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ZOM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ZOM is good value based on its book value relative to its share price (0.53x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.06x)
P/B vs Industry Valuation
ZOM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ZOM due diligence checks available for Premium users.
Be the first to know about important ZOM news, forecast changes, insider trades & much more!
ZOM News
Valuation
ZOM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.71x
Industry
47.66x
Market
41.27x
ZOM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.53x
Industry
2.06x
ZOM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ZOM's financial health
Profit margin
Revenue
$7.3M
Net Income
-$22.0M
Profit Margin
-299.5%
ZOM's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ZOM's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$253.2M
Liabilities
$13.2M
Debt to equity
0.06
ZOM's short-term assets ($99.88M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ZOM's short-term assets ($99.88M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ZOM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ZOM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.0M
Investing
-$3.8M
Financing
$0.0
ZOM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ZOM vs Pharmaceutical Stocks
Zomedica Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.